Dr. Ahlborn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1200 E Ridgewood Ave
Suite 205
Ridgewood, NJ 07450Phone+1 201-689-3646Fax+1 201-389-3851
Summary
- Dr. David Ahlborn is a ABU Board Certified, Urologic Oncologist and Robotic Surgeon with Valley Health System in Paramus, NJ. After graduating from Harvard College in 2011, he received his medical degree from Columbia University Vagelos College of Physicians and Surgeons in 2015. He trained at Mount Sinai Hospital in New York City and completed a fellowship in Urologic Oncology and Robotic Surgery at Hartford Hospital in 2020. He specializes in minimally invasive surgery and surgical oncology and is experienced in robotic urologic surgery and urology.
Education & Training
Hartford HospitalFellowship, Urologic Surgical Oncology, 2020 - 2021
Icahn School of Medicine at Mount SinaiResidency, Urology, 2016 - 2020- Icahn School of Medicine at Mount SinaiInternship, Surgery, 2015 - 2016
Columbia University Vagelos College of Physicians and SurgeonsClass of 2015
Harvard UniversityBA, Neurobiology, Cum Laude, 2007 - 2011
Certifications & Licensure
CT State Medical License 2020 - 2025
NJ State Medical License 2024 - 2025
NY State Medical License 2016 - 2025- American Board of Urology Urology
Publications & Presentations
PubMed
- What is the most effective way to ensure that patients successfully undergo germline testing for prostate cancer?David Ahlborn, Ilene Staff, Tara McLaughlin, Joseph Tortora, Joseph Wagner
Urologic Oncology. 2023-01-01 - 5 citationsMinimally invasive adrenal surgery: virtue or vice?Jared S. Winoker, David Ahlborn, Olamide Omidele, Gustavo Fernandez-Ranvier, Ithaar Derweesh
Future Oncology. 2018-01-18 - 7 citationsOncologic Outcomes of Definitive Treatments for Low- and Intermediate-Risk Prostate Cancer After a Period of Active Surveillance.Michael J. Whalen, Jamie S. Pak, Danny Lascano, David Ahlborn, Justin T. Matulay
Clinical Genitourinary Cancer. 2017-10-01
Professional Memberships
- American Urological AssociationMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
